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Total skin electron irradiation (TSEI) is an effective
option for cutaneous T-cell lymphoma (CTCL).1,2 Two
conventional methods used to deliver TSEI are the Stanford
multiple dual ﬁeld technique and the McGill rotational
technique3,4; however, both techniques require patients to
stand for 10 to 30 minutes and cannot be used in non-
ambulatory patients. Our group has previously described
technical parameters for “lying-on-the-ﬂoor” total skin
electron beam therapy for nonambulatory patients.5Wenow
report clinical implementation of this technique in a non-
ambulatory patient with progressive CTCL with particular
emphasis on the critical importance of in vivo dosimetry.Case presentation
A 67-year-old male with progressive CTCL was seen
for consideration of palliative radiation therapy 14 monthsConﬂicts of interest: None.
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/after his original diagnosis. Symptoms and ﬁndings at the
time of diagnosis had included an intensely pruritic,
diffuse, erythematous truncal rash. Multiple biopsies
demonstrated atypical dermatotropic lymphoid inﬁltrate
consistent with CTCL. He had received 3 different
courses of systemic therapy including: cyclophospha-
mide, hydroxydaunorubicin, vincristine, and prednisone
chemotherapy; romidepsin; and bexarotene before pre-
senting for radiation therapy. He presented with extensive
disease, including multiple ulcerative lesions (Fig 1). The
plantar surfaces of his feet were spared by his disease
process. He was treated initially with a course of con-
ventional standing TSEI without supplemental irradiation
to the soles of the feet, 16 Gy in 4 fractions given
approximately every 7 to 10 days.6
Initial TSEI was well tolerated; 2 months later, he had
near complete response (Fig 2) of his cutaneous disease
except for the soles of his feet where he had progression.
A total of 8 Gy in 2 fractions to this area resulted in
complete response. He was then started on bendamustine
and methylprednisolone after further workup revealed
innumerable pulmonary nodules histologically conﬁrmed
to be T-cell lymphoma.
Approximately 4 weeks later, he returned for re-
evaluation with extensive cutaneous recurrence. Hisof the American Society for Radiation Oncology. This is an open access
by-nc-nd/4.0/).
Figure 2 Patient 2 months after total skin electron irradiation.
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gesting a mixed response to the bendamustine and
methylprednisolone. His overall condition had deterio-
rated and he was no longer able to stand for treatment.
As such, a lying-on-the-ﬂoor TSEI technique was rec-
ommended. He was treated using this technique with an
additional 12 Gy in 3 fractions, in which each fraction
was delivered every 7 to 10 days (minor variation
resulted from patient and physician availability). His
cutaneous disease was well controlled with results
similar to Fig 2. Two additional brief courses of single
fraction (4 Gy) TSEI were sufﬁcient to maintain skin
integrity until the patient died of respiratory failure
resulting from progressive pulmonary involvement by
his lymphoma 6 months after his initial radiation
oncology consultation.Lying-on-the-ﬂoor TSEI technique
Other investigators have described techniques for total
skin electron beam therapy for nonambulatory patients.4,7
A major modiﬁcation in our technique is the use of a
customized copper ﬂattening ﬁlter to improve treatment
ﬁeld uniformity, which eliminates the need for ﬁeld
junctioning and minimizes setup time.5 This technique
also does not require match lines. Treatment was deliv-
ered with 6-MeV electrons. A polycarbonate spoiler
(2 m  1 m  4 mm) was used for electron scatter and
beam energy degradation.
The patient setup is depicted in Figs 3 and 4. The 6
conventional standing positions1,4 are reproduced on the
ﬂoor and described here. For the anteroposterior (AP) and
posteroanterior (PA) positions, the patient’s umbilicus is
positioned either supine or prone directly below the iso-
center with the skin surface about 5 cm below the poly-
carbonate spoiler, and the patient is oriented
perpendicular to the LINAC waveguide. The patient lies
on a thin mattress (about 3 cm thick) with arms and legsFigure 1 Patient’s initial presentation to radiation oncology
after 3 different courses of systemic therapy and before total skin
electron irradiation.partially away from the body and ﬁngers spread apart.
Three gantry angles of 0, 60, and 300 were used to
provide optimal dose homogeneity for both the AP and
PA positions. Monitor unit (MU) weighting for the gantry
angles, which were empirically determined and described
previously,5 were MU300 equal to MU60, and MU0
equal to 0.41 MU60 to account for the fact that the MU0
delivers more dose per MU than the 60 and 300 beams.
The left posterior oblique, right posterior oblique, left
anterior oblique, and right anterior oblique positions are
set up with the patient oriented parallel to the waveguide
and the umbilicus at a distance of 230 cm from the iso-
center, with a gantry setting of 300. The polycarbonate
spoiler is positioned adjacent to the patient as depicted in
Fig 4.
Calibration of the treatment has also been previously
described.5 In brief, a parallel plate ion chamber
(Advanced Markus Type No. TN34045; PTW, Freiburg,
Germany) and solid water was used under standard
reference conditions of a 10  10 cm2 cone size, 100 cm
sourceeskin distance, and 1.3 cm depth to obtain a cGy/
nC conversion factor for the 6-MeV beam on high dose
rate total skin electron mode. This provided a measured
dose per unit charge collected in the chamber. The
chamber and solid water was then put into a position more
representative of the patient’s anatomy during treatment.
In our patient’s case, this consisted of putting the chamber
surface about 25 cm above the ﬂoor and the spoiler 5 cm
above the chamber. Pragmatically, the chamber surface
should be at the same point as the nominal prescription
point, the umbilicus. We then use 30  40 cm2 ﬁelds with
the custom copper ﬁlter in place to scatter the electrons
and deliver 1000 MU at gantry angles of 0, 60, and
300. A similar procedure is performed for the oblique
ﬁelds. The chamber and solid water is placed behind the
spoiler again and the assembly is angled to 60 to mimic
the oblique slope of the patient’s body when lying down.
This setup allowed us to determine the monitor units
needed to deliver the prescription dose under ideal
conditions.
Figure 3 Lying-on-the-ﬂoor total skin electron irradiation setup with the customized ﬂattening ﬁlter technique. (A) Radiochromic ﬁlm
was used at various anatomical locations for in vivo measurements. (B) Schematic of anteroposterior and posteroanterior treatment ﬁelds
(adapted from Deufel and Antolak5; used with permission). Note that only the anteroposterior setup is shown here. (C-E) The patient is
oriented perpendicular to the LINAC waveguide (prone treatment ﬁelds not illustrated). His umbilicus was positioned directly below the
central axis, 5 cm from the spoiler, and the gantry was angled to 300, 0, and 60, respectively.
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factor that takes into account the dose delivered to a
point on the patient as they rotate through all of the
positions, was also incorporated as previously
described.5 For body factor measurements, radiochromic
ﬁlm (Gafchromic EBT3; International Specialty Products
Inc, Wayne, NJ) was afﬁxed to the surface of the
RANDO anthropomorphic phantom (The Phantom
Laboratory, Salem, NY) in 60 increments. A body
factor of 3.1 was calculated as the ratio of the summed
dose delivered to a point on a standard anthropomorphic
phantom transitioned through all treatment ﬁelds depic-
ted in Figs 3 and 4 to the dose delivered from a single
AP treatment ﬁeld. However, we subsequently learned
that the body factor on the phantom was larger than the
patient’s in vivo body factor.
In vivo dosimetric measurements allowed adjustments
of dose delivery. In the previously published technical
details of this approach, radiochromic ﬁlm showed
excellent agreement with ionization chamber results, anda ﬁlm calibration curve showed that the standard
deviation of dose (200 cGy delivered) was <1.3%
between any given piece of ﬁlm.5 Veriﬁcation of the
radiochromic ﬁlm’s accuracy and reproducibility using
the lying-on-the-ﬂoor technique was demonstrated by
previously comparing the normalized dose by anatomic
site in both the Stanford standing technique and the
lying-on-the-ﬂoor technique.5 These measurements were
made by taping pieces of 2  2 cm2 radiochromic ﬁlm
onto the patient’s skin at representative locations on the
head and neck, torso, and extremities. Setup time limi-
tations made it impractical to measure all sites for every
treatment. The radiochromic ﬁlm was covered with a
layer of plastic wrap so that the ﬁlm itself did not come
into direct contact with the patient’s skin and cleaning of
the ﬁlm was not necessary before analysis. Doses
obtained from in vivo measurements are presented in
Table 1. Dosimetry was obtained at the level of the
umbilicus anteriorly, posteriorly, and lateral to the left of
the umbilicus at every treatment. Eighteen other sites
Figure 4 The left posterior oblique, right posterior oblique,
left anterior oblique, and right anterior oblique positions were
delivered with the gantry rotated to 300 with the patient ori-
ented parallel to the LINAC waveguide and the umbilicus
approximately 230 cm from isocenter (supine treatment ﬁelds
not illustrated).
Table 1 In vivo dosimetric measurements
Location Fraction 1 (400 cGy)
Dose (cGy) % of 400 cGy
Umbilicus, anterior 320 80
Umbilicus, left anterior oblique* 232 58
Umbilicus,
right anterior oblique*
Umbilicus, posterior 315 79
Umbilicus,
left posterior oblique*
Umbilicus,
right posterior oblique*
Upper back
Posterior neck 406 102
Right lateral shoulder
Right forearm 274 69
Left anterior thigh
Left posterior calf
Left dorsal foot 327 82
Left anterior wrist
Anterior chest
Right anterior thigh
Right lateral hip 363 91
Right anterior shin
Right posterior calf 276 69
Forehead 293 73
Average 312 78
* For these sites, in vivo dosimetry was obtained at the intersection of th
anterior oblique, left posterior oblique, and right posterior oblique ﬁelds.
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in vivo dose measurement was 78% of the prescription
dose of 400 cGy for the ﬁrst fraction. Monitor units were
cautiously increased by 10% for the second treatment
with a goal of achieving an average dose of 90% of the
prescription. Furthermore, during the second treatment,
additional ﬁlms were used to measure an in vivo
body factor and check the delivered dose for each ﬁeld.
The body factor was calculated in vivo to be 2.7 as
opposed to the 3.1 measured with a rigid phantom,
approximately 15% lower. The average in vivo dose
measurement for the second fraction was 87% of the
prescribed 400 cGy. The MUs were increased by an
additional 15% for the third fraction, resulting in an
average in vivo dose measurement of 99% of the pre-
scribed 400 cGy.Discussion
In vivo dosimetry was critical for successful treatment
delivery. MUs delivered were systematically increased
on progressive treatments according to the in vivo
measurements obtained with radiochromic ﬁlm. Second,Fraction 2 (400 cGy) Fraction 3 (400 cGy)
Dose (cGy) % of 400 cGy Dose (cGy) % of 400 cGy
363 91 396 99
331 83 349 87
302 76 301 75
339 85 401 100
377 94 466 117
348 87 366 92
359 90 421 105
412 103
309 77 349 87
309 77
328 82
348 87 395 99
454 114
398 100
399 100
458 115
424 106
335 84
349 87 394 99
e central axis and the patient’s body for the left anterior oblique, right
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was not done before the ﬁrst treatment, and would have
better deﬁned the treatment conditions. There was
approximately a (1.1*1.15)/0.99 Z 1.28 or 28%
discrepancy between the expected and actual doses
observed in vivo. Of the 28%, we believe 15% may be
attributed to the patient-speciﬁc body factor. The
remainder of this dose discrepancy may be attributed to
setup variation, which we propose could largely be
mitigated by a thorough simulation process. Speciﬁcally,
the proposed simulation would have included detailed
measurements of the patient’s physical dimensions on
the treatment ﬂoor. The AP/PA thickness, the lateral
width, and the distance from the patient’s skin surface
(both supine and prone) to the LINAC would have been
useful to accurately represent the locations to which the
calibration parallel plate chamber should be positioned.
After cautiously increasing the monitor units after the
ﬁrst treatment, the discrepancy between the in vivo
measured dose and the expected dose prompted further
evaluation of another potential contributing factor: the
body factor. The patient-speciﬁc body factor during the
actual treatment was 2.7 versus 3.1 measured on a rigid
anthropomorphic phantom. Using the phantom during
the commissioning of this technique, the estimated body
factor was approximately 15% greater than the in vivo
measured factor and adjustments had to be made to the
treatment setup on the second day to account for the
patient’s body habitus.Teaching case: Key learning points
This teaching case demonstrates that TSEI may be
effectively used in nonambulatory patients using a lying-
on-the-ﬂoor technique. This case also shows that simu-
lation before the ﬁrst treatment and in vivo measurements
are critical for accurate delivery of dose using this
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